ANNEXON INC (ANNX) Stock News

USA - Nasdaq - NASDAQ:ANNX - US03589W1027 - Common Stock

5.08 USD

+0.04 (+0.79%)

Last: 12/12/2025, 2:35:51 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ANNX Latest News, Press Relases and Analysis

All

Press Releases

23 days ago - By: Benzinga - Mentions: BFLY ZYXI TXMD AGIO ...

12 Health Care Stocks Moving In Wednesday's Intraday Session

a month ago - By: Benzinga - Mentions: ABP CHEK GTBP DMAC ...

12 Health Care Stocks Moving In Friday's After-Market Session

a month ago - By: Annexon Biosciences

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

a month ago - By: Annexon Biosciences

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

a month ago - By: Annexon Biosciences

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Annexon Biosciences

Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Annexon Biosciences

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Annexon Biosciences

Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

a month ago - By: Annexon Biosciences

Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

4 months ago - By: Annexon Biosciences

Annexon Biosciences to Participate in Upcoming September Investor Conferences

4 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: The Motley Fool

Annexon Narrows Loss in Fiscal Q2

4 months ago - By: Annexon Biosciences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

4 months ago - By: Annexon Biosciences

Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

4 months ago - By: Annexon Biosciences

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

4 months ago - By: Annexon Biosciences

Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy

5 months ago - By: Annexon Biosciences

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

5 months ago - By: Annexon Biosciences

Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy

6 months ago - By: Annexon Biosciences

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

6 months ago - By: Annexon Biosciences

Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

7 months ago - By: Annexon Biosciences

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

7 months ago - By: Annexon Biosciences

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

7 months ago - By: Annexon Biosciences

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

7 months ago - By: Annexon Biosciences

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

7 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

7 months ago - By: Annexon Biosciences

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

7 months ago - By: Annexon Biosciences

Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

7 months ago - By: Annexon Biosciences

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

7 months ago - By: Annexon Biosciences

Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting

7 months ago - By: Annexon Biosciences

Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress

8 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Annexon Biosciences

Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)